Member-only story

Why is There a Mad Dash to Manufacture Effective Drugs to Combat the COVID-19 Coronavirus?

Because it’s more lucrative to manage symptoms.

Dr Joel Yong, PhD
5 min readMar 23, 2020
Photo by freestocks on Unsplash

Let’s face it. It’s a sad day when you realise that Big Pharma is in a race to produce pharmaceuticals that can provide help in managing the symptoms of the COVID-19 coronavirus better.

Yup, because that makes more money than supporting immune system function for proper virus elimination.

Most people will be desperate for these drugs, mainly because they don’t know how virus clearance works. So here we go.

The first layer of defence against viruses lies in the form of antibodies. Healthy levels of antibodies in the blood can tag virus particles or virus-infected cells and send them for destruction via autophagy, where their nucleic acids can be digested and reused for the synthesis of new cells.

Our mucous membranes are susceptible to virus breaches from expelled droplets.

Immunoglobulin A (IgA) is an antibody that lines the mucous membranes. Hence, I’d say that a healthy production of IgA is our first layer of immunity protection.

When the antibodies have tagged the viruses and the infected cells for destruction, the macrophages in our immune system commence the…

--

--

Dr Joel Yong, PhD
Dr Joel Yong, PhD

Written by Dr Joel Yong, PhD

Crafting strategies for optimising the biochemical pathways in the human body. Learn more at https://thethinkingscientist.substack.com.

Responses (1)